Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.77 |
| ▸ | TFEB | P19484 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 6/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | BCHE | P06276 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 3/20 | 0.62 |
| ▸ | AR | P10275 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.60 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644527 | 1.00 | KDM4E (1.00) | KDM4ENFE2L2TFEBMAPTNPC1 | |
| SCHEMBL644526 | 1.00 | KDM4E (1.00) | KDM4ENFE2L2TFEBMAPTNPC1 | |
| SCHEMBL29805195 | 0.87 | NFE2L2 (1.00) | KDM4ENFE2L2TFEBMAPTNPC1 | |
| SCHEMBL30307386 | 0.87 | NFE2L2 (1.00) | KDM4ENFE2L2TFEBMAPTNPC1 | |
| SCHEMBL16403662 | 0.87 | NFE2L2 (1.00) | KDM4ENFE2L2TFEBMAPTNPC1 | |
| SCHEMBL2744044 | 0.87 | NFE2L2 (1.00) | KDM4ENFE2L2TFEBMAPTNPC1 | |
| SCHEMBL2744047 | 0.87 | NFE2L2 (1.00) | KDM4ENFE2L2TFEBMAPTNPC1 | |
| Coumarinic Acid Methyl Ether SCHEMBL714857 | 0.85 | NFE2L2 (0.77) | KDM4ENFE2L2TFEBMAPTNPC1 | |
| Coumarinic Acid Methyl Ether SCHEMBL29369917 | 0.85 | NFE2L2 (0.77) | KDM4ENFE2L2TFEBMAPTNPC1 | |
| Coumarinic Acid Methyl Ether SCHEMBL79060 | 0.85 | NFE2L2 (0.77) | KDM4ENFE2L2TFEBMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727923-A1 | TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA | University of Georgia Research Foundation, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260098012-A1 | TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2024258904-A1 | TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| CN-113304129-B | Application of mono-ketene monocarbonyl curcumin analogue in preparing antioxidant drugs | 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） | 2022-11-08 | — | — | CN | disclosed |
| CN-112266352-B | Piperlongumine derivative and preparation method and application thereof | 绍兴文理学院 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098012-A1 | TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA | CD47, SLC11A2, G6PD | KDM4E 1264/4885NFE2L2 1496/4885TFEB 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.